Journal Home > Volume 14 , Issue 9
Nano Research 2021, 14(9): 3319-3328 https://doi.org/10.1007/s12274-021-3413-8
Research Article | Issue | Published: 26 April 2021

Systemic delivery of microRNA for treatment of brain ischemia

Show Author's Information Chaoyong Liu1,2,3,§,  Jing Wen7,§,  Dai Li1,2,§,  Hongzhao Qi6,  Lina Nih4,  Jialin Zhu1,2,  Duo Xu4,  Yu Ren8,  Shanshan Zhang6,  Donglin Han6,  Huanhuan Jia8,  Junhu Zhou1,2,  Meng Qin3,  Jialing Wu9,  Xubo Yuan6,  Ji Liu5( ),  Jin Zhao6( ),  Chunsheng Kang1,2 ( ),  Yunfeng Lu4( )
Department of Neurosurgery, Tianjin Medical University General Hospital, Tianjin 300052, China
Key Laboratory of Post-Trauma Neuro-repair and Regeneration in Central Nervous System, Ministry of Education, Tianjin Key Laboratory of Injuries, Variations and Regeneration of Nervous System, Tianjin Neurological Institute, Tianjin 300052, China
College of Life Science and Technology and Beijing Advanced Innovation Center for Soft Matter Science and Engineering, Beijing University of Chemical Technology, Beijing 100029, China
Department of Chemical and Biomolecular Engineering, University of California, Los Angeles, Los Angeles, CA 90095, USA
Department of Medicine, Tianjin Huanhu Hospital, Tianjin 300350, China
Tianjin Key Laboratory of Composite and Functional Materials, School of Materials Science and Engineering, Tianjin University, Tianjin 300350, China
Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA
Tianjin Research Center of Basic Medical Science, Tianjin Medical University, Tianjin 300070, China
Department of Neurology, Tianjin Huanhu Hospital, Tianjin 300350, China

§ Chaoyong Liu, Jing Wen, and Dai Li contributed equally to this work.

Keywords:
polymer nanocapsules, small RNA delivery, microRNA-21, brain ischemia
Topics:
Gene therapy
Cite this article:
Liu C, Wen J, Li D, et al. Systemic delivery of microRNA for treatment of brain ischemia. Nano Research, 2021, 14(9): 3319-3328. https://doi.org/10.1007/s12274-021-3413-8
Download citation
EndNote(RIS)
BibTeX

655

Views

40

Downloads

Citations

5

Crossref

5

WoS

5

Scopus

0

CSCD

Abstract Full text Electronic supplementary material About this article

Brain ischemia is the second leading cause of death and the third leading cause of disability in the world. Systemic delivery of microRNA, a class of molecules that regulate the expression of cellular proteins associated with angiogenesis, cell growth, proliferation and differentiation, holds great promise for the treatment of brain ischemia. However, their therapeutic efficacy has been hampered by poor delivery efficiency of microRNA. We report herein a platform technology based on microRNA nanocapsules, which enables their effective delivery to the disease sites in the brain. Exemplified by microRNA-21, intravenous injection of the nanocapsules into a rat model of cerebral ischemia could effectively ameliorate the infarct volume, neurological deficit and histopathological severity.


menu
Abstract
Full text
Outline
Electronic supplementary material
About this article

Systemic delivery of microRNA for treatment of brain ischemia

Show Author's information Chaoyong Liu1,2,3,§, Jing Wen7,§, Dai Li1,2,§, Hongzhao Qi6, Lina Nih4, Jialin Zhu1,2, Duo Xu4, Yu Ren8, Shanshan Zhang6, Donglin Han6, Huanhuan Jia8, Junhu Zhou1,2, Meng Qin3, Jialing Wu9, Xubo Yuan6, Ji Liu5( ), Jin Zhao6( ), Chunsheng Kang1,2 ( ), Yunfeng Lu4( )
Department of Neurosurgery, Tianjin Medical University General Hospital, Tianjin 300052, China
Key Laboratory of Post-Trauma Neuro-repair and Regeneration in Central Nervous System, Ministry of Education, Tianjin Key Laboratory of Injuries, Variations and Regeneration of Nervous System, Tianjin Neurological Institute, Tianjin 300052, China
College of Life Science and Technology and Beijing Advanced Innovation Center for Soft Matter Science and Engineering, Beijing University of Chemical Technology, Beijing 100029, China
Department of Chemical and Biomolecular Engineering, University of California, Los Angeles, Los Angeles, CA 90095, USA
Department of Medicine, Tianjin Huanhu Hospital, Tianjin 300350, China
Tianjin Key Laboratory of Composite and Functional Materials, School of Materials Science and Engineering, Tianjin University, Tianjin 300350, China
Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA
Tianjin Research Center of Basic Medical Science, Tianjin Medical University, Tianjin 300070, China
Department of Neurology, Tianjin Huanhu Hospital, Tianjin 300350, China

§ Chaoyong Liu, Jing Wen, and Dai Li contributed equally to this work.

Abstract

Brain ischemia is the second leading cause of death and the third leading cause of disability in the world. Systemic delivery of microRNA, a class of molecules that regulate the expression of cellular proteins associated with angiogenesis, cell growth, proliferation and differentiation, holds great promise for the treatment of brain ischemia. However, their therapeutic efficacy has been hampered by poor delivery efficiency of microRNA. We report herein a platform technology based on microRNA nanocapsules, which enables their effective delivery to the disease sites in the brain. Exemplified by microRNA-21, intravenous injection of the nanocapsules into a rat model of cerebral ischemia could effectively ameliorate the infarct volume, neurological deficit and histopathological severity.

Keywords: polymer nanocapsules, small RNA delivery, microRNA-21, brain ischemia

References(54)

[1]
Isner, J. M. Tissue responses to ischemia: Local and remote responses for preserving perfusion of ischemic muscle. J. Clin. Invest. 2000, 106, 615-619.
DOI Google Scholar
[2]
Semenza, G. L. Series introduction: Tissue ischemia: Pathophysiology and therapeutics. J. Clin. Invest. 2000, 106, 613-614.
DOI Google Scholar
[3]
Eltzschig, H. K.; Eckle, T. Ischemia and reperfusion—From mechanism to translation. Nat. Med. 2011, 17, 1391-1401.
DOI Google Scholar
[4]
Upadhyay, R. K. Drug delivery systems, CNS protection, and the blood brain barrier. BioMed Res. Int. 2014, 2014, 869269.
DOI Google Scholar
[5]
Rosenberg, G. A. Neurological diseases in relation to the blood-brain barrier. J. Cereb. Blood Flow Metab. 2012, 32, 1139-1151.
DOI Google Scholar
[6]
Gállego, J.; Muñoz, R.; Martínez-Vila, E. Emergent cerebrovascular disease risk factor weighting: Is transient ischemic attack an imminent threat? Cerebrovasc. Dis. 2009, 27, 88-96.
DOI Google Scholar
[7]
Luengo-Fernandez, R.; Gray, A. M.; Rothwell, P. M. Costs of stroke using patient-level data: A critical review of the literature. Stroke 2009, 40, e18-e23.
DOI Google Scholar
[8]
Novakovic, R.; Toth, G.; Purdy, P. D. Review of current and emerging therapies in acute ischemic stroke. J. Neurointerv. Surg. 2009, 1, 13-26.
DOI Google Scholar
[9]
Hankey, G. J. Stroke. Lancet 2017, 389, 641-654.
DOI Google Scholar
[10]
Lee, J. M.; Grabb, M. C.; Zipfel, G. J.; Choi, D. W. Brain tissue responses to ischemia. J. Clin. Invest. 2000, 106, 723-731.
DOI Google Scholar
[11]
Hacke, W.; Kaste, M.; Bluhmki, E.; Brozman, M.; Dávalos, A.; Guidetti, D.; Larrue, V.; Lees, K. R.; Medeghri, Z.; Machnig, T. et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N. Engl. J. Med. 2008, 359, 1317-1329.
DOI Google Scholar
[12]
Goyal, M.; Yu, A. Y. X.; Menon, B. K.; Dippel, D. W. J.; Hacke, W.; Davis, S. M.; Fisher, M.; Yavagal, D. R.; Turjman, F.; Ross, J. et al. Endovascular therapy in acute ischemic stroke. Stroke 2016, 47, 548-553.
DOI Google Scholar
[13]
Del Zoppo, G. J.; Saver, J. L.; Jauch, E. C.; Adams, H. P., Jr.; American Heart Association Stroke Council. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: A science advisory from the American Heart Association/American Stroke Association. Stroke 2009, 40, 2945-2948.
DOI Google Scholar
[14]
Emberson, J.; Lees, K. R.; Lyden, P.; Blackwell, L.; Albers, G.; Bluhmki, E.; Brott, T.; Cohen, G.; Davis, S.; Donnan, G. et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: A meta-analysis of individual patient data from randomised trials. Lancet 2014, 384, 1929-1935.
DOI Google Scholar
[15]
Mead, G. E.; Hsieh, C. F.; Lee, R.; Kutlubaev, M. A.; Claxton, A.; Hankey, G. J.; Hackett, M. L. Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. Cochrane Database Syst. Rev. 2012, 11, CD009286.
DOI Google Scholar
[16]
Mortensen, J. K.; Andersen, G. Safety of selective serotonin reuptake inhibitor treatment in recovering stroke patients. Expert Opin. Drug Saf. 2015, 14, 911-919.
DOI Google Scholar
[17]
Prasad, K.; Sharma, A.; Garg, A.; Mohanty, S.; Bhatnagar, S.; Johri, S.; Singh, K. K.; Nair, V.; Sarkar, R. S.; Gorthi, S. P. et al. Intravenous autologous bone marrow mononuclear stem cell therapy for ischemic stroke: A multicentric, randomized trial. Stroke 2014, 45, 3618-3624.
DOI Google Scholar
[18]
Kalladka, D.; Sinden, J.; Pollock, K.; Haig, C.; McLean, J.; Smith, W.; McConnachie, A.; Santosh, C.; Bath, P. M.; Dunn, L. et al. Human neural stem cells in patients with chronic ischaemic stroke (PISCES): A phase 1, first-in-man study. Lancet 2016, 388, 787-796.
DOI Google Scholar
[19]
Beavers, K. R.; Nelson, C. E.; Duvall, C. L. MiRNA inhibition in tissue engineering and regenerative medicine. Adv. Drug Deliv. Rev. 2015, 88, 123-137.
DOI Google Scholar
[20]
Inui, M.; Martello, G.; Piccolo, S. MicroRNA control of signal transduction. Nat. Rev. Mol. Cell Biol. 2010, 11, 252-263.
DOI Google Scholar
[21]
Caputo, M.; Saif, J.; Rajakaruna, C.; Brooks, M.; Angelini, G. D.; Emanueli, C. MicroRNAs in vascular tissue engineering and post-ischemic neovascularization. Adv. Drug Deliv. Rev. 2015, 88, 78-91.
DOI Google Scholar
[22]
Liang, T. Y.; Lou, J. Y. Increased expression of mir-34a-5p and clinical association in acute ischemic stroke patients and in a rat model. Med. Sci. Monit. 2016, 22, 2950-2955.
DOI Google Scholar
[23]
Zhao, H. P.; Wang, J.; Gao, L.; Wang, R. L.; Liu, X. R.; Gao, Z.; Tao, Z.; Xu, C. M.; Song, J. X.; Ji, X. M. et al. MiRNA-424 protects against permanent focal cerebral ischemia injury in mice involving suppressing microglia activation. Stroke 2013, 44, 1706-1713.
DOI Google Scholar
[24]
Buller, B.; Liu, X. S.; Wang, X. L.; Zhang, R. L.; Zhang, L.; Hozeska-Solgot, A.; Chopp, M.; Zhang, Z. G. MicroRNA-21 protects neurons from ischemic death. FEBS J. 2010, 277, 4299-4307.
DOI Google Scholar
[25]
Chen, Y. C.; Gao, D. Y.; Huang, L. In vivo delivery of miRNAs for cancer therapy: Challenges and strategies. Adv. Drug Deliv. Rev. 2015, 81, 128-141.
DOI Google Scholar
[26]
Kim, J.; Cao, L.; Shvartsman, D.; Silva, E. A.; Mooney, D. J. Targeted delivery of nanoparticles to ischemic muscle for imaging and therapeutic angiogenesis. Nano Lett. 2011, 11, 694-700.
DOI Google Scholar
[27]
Pecot, C. V.; Calin, G. A.; Coleman, R. L.; Lopez-Berestein, G.; Sood, A. K. RNA interference in the clinic: Challenges and future directions. Nat. Rev. Cancer 2011, 11, 59-67.
DOI Google Scholar
[28]
Vickers, K. C.; Remaley, A. T. Lipid-based carriers of microRNAs and intercellular communication. Curr. Opin. Lipidol. 2012, 23, 91-97.
DOI Google Scholar
[29]
Crooke, S. T.; Graham, M. J.; Zuckerman, J. E.; Brooks, D.; Conklin, B. S.; Cummins, L. L.; Greig, M. J.; Guinosso, C. J.; Kornbrust, D.; Manoharan, M. et al. Pharmacokinetic properties of several novel oligonucleotide analogs in mice. J. Pharmacol. Exp. Ther. 1996, 277, 923-937.
Google Scholar
[30]
Cheng, C. J.; Bahal, R.; Babar, I. A.; Pincus, Z.; Barrera, F.; Liu, C.; Svoronos, A.; Braddock, D. T.; Glazer, P. M.; Engelman, D. M. et al. MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. Nature 2015, 518, 107-110.
DOI Google Scholar
[31]
Davis, M. E.; Zuckerman, J. E.; Choi, C. H. J.; Seligson, D.; Tolcher, A.; Alabi, C. A.; Yen, Y.; Heidel, J. D.; Ribas, A. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464, 1067-1070.
DOI Google Scholar
[32]
Gibbings, D. J.; Ciaudo, C.; Erhardt, M.; Voinnet, O. Multivesicular bodies associate with components of miRNA effector complexes and modulate miRNA activity. Nat. Cell Biol. 2009, 11, 1143-1149.
DOI Google Scholar
[33]
Yang, Y. P.; Chien, Y.; Chiou, G. Y.; Cherng, J. Y.; Wang, M. L.; Lo, W. L.; Chang, Y. L.; Huang, P. I.; Chen, Y. W.; Shih, Y. H. et al. Inhibition of cancer stem cell-like properties and reduced chemoradioresistance of glioblastoma using microRNA145 with cationic polyurethane-short branch PEI. Biomaterials 2012, 33, 1462-1476.
DOI Google Scholar
[34]
Chiou, G. Y.; Cherng, J. Y.; Hsu, H. S.; Wang, M. L.; Tsai, C. M.; Lu, K. H.; Chien, Y.; Hung, S. C.; Chen, Y. W.; Wong, C. I. et al. Cationic polyurethanes-short branch PEI-mediated delivery of Mir145 inhibited epithelial-mesenchymal transdifferentiation and cancer stem-like properties and in lung adenocarcinoma. J. Control. Release 2012, 159, 240-250.
DOI Google Scholar
[35]
Kanasty, R.; Dorkin, J. R.; Vegas, A.; Anderson, D. Delivery materials for siRNA therapeutics. Nat. Mater. 2013, 12, 967-977.
DOI Google Scholar
[36]
Zhang, Y.; Wang, Z. J.; Gemeinhart, R. A. Progress in microRNA delivery. J. Control. Release 2013, 172, 962-974.
DOI Google Scholar
[37]
Hwang, D. W.; Son, S.; Jang, J.; Youn, H.; Lee, S.; Lee, D.; Lee, Y. S.; Jeong, J. M.; Kim, W. J.; Lee, D. S. A brain-targeted rabies virus glycoprotein-disulfide linked PEI nanocarrier for delivery of neurogenic microRNA. Biomaterials 2011, 32, 4968-4975.
DOI Google Scholar
[38]
Zhang, S. L.; Li, J.; Lykotrafitis, G.; Bao, G.; Suresh, S. Size-dependent endocytosis of nanoparticles. Adv. Mater. 2009, 21, 419-424.
DOI Google Scholar
[39]
David, S.; Pitard, B.; Benoît, J. P.; Passirani, C. Non-viral nanosystems for systemic siRNA delivery. Pharmacol. Res. 2010, 62, 100-114.
DOI Google Scholar
[40]
Ge, X. T.; Lei, P.; Wang, H. C.; Zhang, A. L.; Han, Z. L.; Chen, X.; Li, S. H.; Jiang, R. C.; Kang, C. S.; Zhang, J. N. miR-21 improves the neurological outcome after traumatic brain injury in rats. Sci. Rep. 2014, 4, 6718.
DOI Google Scholar
[41]
Shi, S. J.; Han, L.; Gong, T.; Zhang, Z. R.; Sun, X. Systemic delivery of microRNA-34a for cancer stem cell therapy. Angew. Chem., Int. Ed. 2013, 52, 3901-3905.
DOI Google Scholar
[42]
Gref, R.; Domb, A.; Quellec, P.; Blunk, T.; Müller, R. H.; Verbavatz, J. M.; Langer, R. The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv. Drug Deliv. Rev. 1995, 16, 215-233.
DOI Google Scholar
[43]
White, R. E.; Giffard, R. G. MicroRNA-320 induces neurite outgrowth by targeting ARPP-1. NeuroReport 2012, 23, 590-595.
DOI Google Scholar
[44]
Liu, T. L.; Li, L. L.; Fu, C. H.; Liu, H. Y.; Chen, D.; Tang, F. Q. Pathological mechanisms of liver injury caused by continuous intraperitoneal injection of silica nanoparticles. Biomaterials 2012, 33, 2399-2407.
DOI Google Scholar
[45]
Oladipupo, S.; Hu, S.; Kovalski, J.; Yao, J. J.; Santeford, A.; Sohn, R. E.; Shohet, R.; Maslov, K.; Wang, L. V.; Arbeit, J. M. VEGF is essential for hypoxia-inducible factor-mediated neovascularization but dispensable for endothelial sprouting. Proc. Natl. Acad. Sci. USA 2011, 108, 13264-13269.
DOI Google Scholar
[46]
Zhang, P.; Lei, X. H.; Sun, Y.; Zhang, H. T.; Chang, L.; Li, C. L.; Liu, D. M.; Bhatta, N.; Zhang, Z. R.; Jiang, C. L. Regenerative repair of Pifithrin-α in cerebral ischemia via VEGF dependent manner. Sci. Rep. 2016, 6, 26295.
DOI Google Scholar
[47]
Deshpande, N.; Ren, Y.; Foygel, K.; Rosenberg, J.; Willmann, J. K. Tumor angiogenic marker expression levels during tumor growth: Longitudinal assessment with molecularly targeted microbubbles and US imaging. Radiology 2011, 258, 804-811.
DOI Google Scholar
[48]
Yang, Z. H.; Wang, K. K. W. Glial fibrillary acidic protein: From intermediate filament assembly and gliosis to neurobiomarker. Trends Neurosci. 2015, 38, 364-374.
DOI Google Scholar
[49]
Yan, M.; Liang, M.; Wen, J.; Liu, Y.; Lu, Y. F.; Chen, I. S. Y. Single siRNA nanocapsules for enhanced RNAi delivery. J. Am. Chem. Soc. 2012, 134, 13542-13545.
DOI Google Scholar
[50]
Liang, S.; Liu, Y.; Jin, X.; Liu, G.; Wen, J.; Zhang, L. L.; Li, J.; Yuan, X. B.; Chen, I. S. Y.; Chen, W. et al. Phosphorylcholine polymer nanocapsules prolong the circulation time and reduce the immunogenicity of therapeutic proteins. Nano Res. 2016, 9, 1022-1031.
DOI Google Scholar
[51]
Liu, C. Y.; Wen, J.; Meng, Y. B.; Zhang, K. L.; Zhu, J. L.; Ren, Y.; Qian, X. M.; Yuan, X. B.; Lu, Y. F.; Kang, C. S. Efficient delivery of therapeutic miRNA nanocapsules for tumor suppression. Adv. Mater. 2015, 27, 292-297.
DOI Google Scholar
[52]
Gu, Z.; Yan, M.; Hu, B. L.; Joo, K. I.; Biswas, A.; Huang, Y.; Lu, Y. F.; Wang, P.; Tang, Y. Protein nanocapsule weaved with enzymatically degradable polymeric network. Nano Lett. 2009, 9, 4533-4538.
DOI Google Scholar
[53]
Liu, X.; An, C. Y.; Jin, P.; Liu, X. S.; Wang, L. H. Protective effects of cationic bovine serum albumin-conjugated PEGylated tanshinone IIA nanoparticles on cerebral ischemia. Biomaterials 2013, 34, 817-830.
DOI Google Scholar
[54]
Pignataro, G.; Scorziello, A.; Di Renzo, G.; Annunziato, L. Post-ischemic brain damage: Effect of ischemic preconditioning and postconditioning and identification of potential candidates for stroke therapy. FEBS J. 2009, 276, 46-57.
DOI Google Scholar
File
12274_2021_3413_MOESM1_ESM.pdf (5.6 MB)
Publication history
Copyright
Acknowledgements

Publication history

Received: 14 November 2020
Revised: 10 February 2021
Accepted: 22 February 2021
Published: 26 April 2021
Issue date: September 2021

Copyright

© Tsinghua University Press and Springer-Verlag GmbH Germany, part of Springer Nature 2021

Acknowledgements

This work was supported by the National Key Research and Development Program of China (No. 2019YFA0903801), the National Natural Science Foundation of China (Nos. 52073015, 51773151, 52003021, and 81671169), Tianjin Municipal Health Bureau (No. 2010KY11), Postdoctoral Science Foundation of China (No. 2015M580212), and Fundamental Research Funds for the Central Universities (No. ZY2006).

Return